Pharmafoods Revises Earnings Forecast — Profit Up 30% Despite Revenue Decline
Pharmafoods (TSE:2929) has revised its earnings forecast for the fiscal year ending July 2026, raising operating profit guidance by 30% while lowering revenue expectations, signaling a strategic pivot toward profitability over top-line growth.
| Item | Before | After | Change |
|---|---|---|---|
| Revenue | JPY 67.0bn | JPY 63.2bn | -5.7% |
| Operating Profit | JPY 2.00bn | JPY 2.60bn | +30.0% |
| Ordinary Income | JPY 2.00bn | JPY 2.40bn | +20.0% |
| 親会社株主に帰属する当期純利益 | JPY 1.50bn | JPY 1.95bn | +30.0% |
| １株当たり当期純利益 | JPY 51.65/share | JPY 67.14/share | +JPY 15.49/share |
The company attributed the revision to a deliberate shift in business strategy. Facing changing market conditions, Pharmafoods is prioritizing profitability and capital efficiency over revenue expansion. Management has implemented rigorous cost controls and selective investment across all business divisions, emphasizing margin-accretive sales activities. Operating profit is now projected to exceed the prior fiscal year’s actual results, demonstrating the effectiveness of this operational discipline.
The revision underscores management’s commitment to sustainable, profitable growth. While revenue is expected to decline by JPY 3.8bn, the company has achieved substantial margin expansion, with operating profit rising JPY 600M and net profit attributable to parent shareholders increasing JPY 450M. Earnings per share are forecast to climb to JPY 67.14/share from JPY 51.65/share, a 30% increase. This earnings quality improvement—coupled with stronger ordinary income (keijo rieki), a Japan-specific metric capturing non-operating financial items—suggests the company is executing a successful transition toward a more capital-efficient business model.
Source: Original filing (TDnet) | 日本語版
This article is for informational purposes only and does not constitute investment advice. Always verify against the original filing.